Article

Wavefront-guided PRK after previous keratorefractive surgery safe, effective in study

Wavefront-guided PRK in eyes with high aberrations after keratorefractive surgery was highly predictable and safe, with the vast majority of patients within 0.50 D of the intended correction, said Edward Manche, MD, of Stanford University School of Medicine, Stanford, CA.

Wavefront-guided PRK in eyes with high aberrations after keratorefractive surgery was highly predictable and safe, with the vast majority of patients within 0.50 D of the intended correction, said Edward Manche, MD, of Stanford University School of Medicine, Stanford, CA.

The study included 25 eyes of 21 patients. Fourteen patients had undergone a previous LASIK, nine had had radial keratotomy, and two had had PRK. All patients were treated with the VISX S4 excimer laser and the VISX WaveScan aberrometer.

Dr. Manche reported that there was a significant transient hyperopic overshoot 1 month after the treatment, especially in the patients who had undergone a previous LASIK procedure. He reported that 61% of patients had 20/20 or better.

The predictability of the PRK was very good, with 83% of patients within 0.50 D of the intended correction. No complications developed. All eyes had completely re-epithelialized in 7 days and no haze developed.

The safety was excellent. At 6 months, 23% had a one line or greater increase in the best-corrected visual acuity. At this time point, the uncorrected visual acuity had improved to 20/16.

Patients reported resolution of ghosting of vision. The topography was markedly improved with better centration, and there was a significant decrease in total root mean square values and specifically coma.

"We obtained excellent uncorrected visual acuity and best spectacle-corrected visual acuity, with 23% of eyes having an increase of one or more lines of best-corrected vision at 6 months," Dr. Manche said. "The safety and predictability of the procedure were excellent. There was a significant delay in uncorrected and best spectacle-corrected visual recovery. There was a slight reduction in the total root-mean-square values and not change in trefoil or spherical aberration."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.